Wu et al. compare people with cancer receiving heart-damaging therapies with and without glucagon-like peptide-1 receptor agonist treatment. Use of these medications is associated with lower risks of treatment-related heart damage, mortality, hospitalization, and cardiovascular complications, particularly in patients with diabetes.
- Jheng-Yan Wu
- Yu-Min Lin
- Wei-Ting Chang
